Clinical study of a new antikeloid agent.
An old healing drug has been assessed and found to be of clinical value in stopping the inflammatory phase of hypertrophic scars and keloids. So far, this drug has no known side effects other than occasional mild gastric intolerance and allergic reaction. Our findings are well supported in the literature. The effect of the drug on other forms of connective tissue anomalies that present an inflammatory phase is similar to that on keloids, gradually brining scars to the maturation phase. Our results on this will be published later. Madecassol has also been shown to have a preventive effect on burn and postoperative hypertrophic scars. It compares favorably in effectiveness with compression bandaging, and gives more lasting results than intralesional cortisone or radiation therapy. Finally, Madecassol has a placebo effect of 29%-well within acceptable limits.
D000328:Adult; D002056:Burns / Q000150:complications; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006027:Glycosides / Q000627:therapeutic use*; D006801:Humans; D007627:Keloid / Q000188:drug therapy*; D010919:Placebos; D010936:Plant Extracts / Q000627:therapeutic use; D013997:Time Factors; D014315:Triterpenes / Q000627:therapeutic use*; D014945:Wound Healing
D006027:Glycosides; D010919:Placebos; D010936:Plant Extracts; D014315:Triterpenes; C004446:asiaticoside